At Japan IT Week Spring 2026, Enabling IEC 62443-4-1–Aligned Security and Real-Time Intelligence Across Connected Infrastructure

TOKYO, April 2, 2026 /PRNewswire/ — SINTRONES Technology Corp. (TWSE: 6680), a global provider of rugged embedded and Edge AI computing solutions, will present its IEC 62443-4-1–aligned Edge AI platforms at Japan IT Week Spring 2026 (Tokyo Big Sight, West Hall 4, Booth W25-25). The showcase highlights how Edge AI supports real-time processing, system reliability, and cybersecurity across smart manufacturing, mobility, and mission-critical applications.

“Edge AI is becoming a core enabler of next-generation infrastructure,” said Kevin Hsu, CEO of SINTRONES Technology. “By aligning with IEC 62443-4-1 and focusing on reliability in harsh environments, we support secure and stable AI deployment at the edge across industrial automation, transportation, and mission-critical systems.”

At the exhibition, SINTRONES will present integrated Edge AI scenarios combining hardware platforms with real-world applications. In factory automation, the ABOX-5221 ThermoSiphon™ Edge AI computer, powered by the latest Intel® Core™ processors, delivers stable, high-performance AI inference for precision control. It features fanless ThermoSiphon™ liquid cooling, a backup battery unit for up to 10 minutes of emergency power, a MXM/M.2 dual module architecture for flexible AI acceleration, and dual 10GbE Ethernet for high-speed, redundant transmission, ensuring reliable, real-time operation in harsh industrial environments.

For defense and ISR applications, the ultra-compact IBOX-604-G2, weighing about 0.3 kg, enables real-time sensor fusion and on-device AI processing in drones and unmanned systems where size, weight, and power constraints are critical.

In transportation and mobility infrastructure, the IBOX-650P-IP66 will be showcased for deployment in railway and roadside environments. It features an IP66-rated enclosure, M12 IP67 connectors, and GMSL-2 camera support, designed for stable operation under vibration and outdoor conditions. Target applications include fleet management, passenger information systems, and real-time monitoring.

SINTRONES’ platforms are developed under a secure development lifecycle aligned with IEC 62443-4-1. In parallel, the company aligns with the Intel® AI and Edge ecosystem, leveraging optimized compute architectures and AI acceleration capabilities to support efficient, real-time processing at the edge. This approach enables customers to accelerate AI adoption while maintaining performance, interoperability, and long-term scalability across connected industrial systems.

About SINTRONES
Founded in 2009, SINTRONES Technology Corp. (TWSE: 6680) is a global provider of rugged industrial and Edge AI computing solutions. The company designs modular, certified platforms that enable real-time decision-making at the edge for mission-critical applications across transportation, industrial automation, and military and defence environments. For more info, please visit www.sintrones.jp

MELBOURNE, Australia and INDIANAPOLIS, April 2, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 2026^[1]. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as a NED.

Mr. Gill is a life sciences executive with over 35 years’ experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical (including radiopharmaceuticals) and medical device companies. He currently serves on the boards of Evolus, Inc. (NASDAQ: EOLS), Allucent LLC, Bridge to Life Ltd, RapidPulse Inc. and huMannity Medtec (formerly Alfred Mann Foundation), and was until recently a board member of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Strongbridge Biopharma plc (NASDAQ: SBBP), Alpha Source Inc, Healthtronics, Inc, and Perimetrics, LLC.

Mr. Gill brings deep expertise in capital markets, scaling businesses, governance and corporate turn-around strategy and has served as Chief Financial Officer or President of multiple publicly traded companies, including EndoChoice Holdings, Inc. (NYSE: GI, acquired by Boston Scientific), INC Research (NASDAQ: INCR, now Syneos Health), and CTI Molecular Imaging (NASDAQ: CTMI, acquired by Siemens). He holds a B.S. in Accounting from Wake Forest University and an MBA from Emory University.

Telix Interim Chair, Mark Nelson, commented, “We are pleased to welcome David to the Board, where his strong financial expertise and deep knowledge of U.S. capital markets will be highly valuable. We intend to further strengthen the Board through additional appointments aligned with our growth trajectory and governance needs as a dual-listed company.”

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

• Webull Australia has removed commission on US, Hong Kong, and China A-Share trading.
• The move follows Webull’s existing $0 commission on US and Australian ETFs, completing its transition to zero-commission trading across key asset classes.
• Webull Australia is now the only major Australian platform offering $0 commission across US, Hong Kong, and China A-Share markets from a single app – and one of the lowest-cost platforms in Australia.
• Webull Australia has won the WeMoney 2026 Award for Best Low-Cost Broker.

SYDNEY, April 2, 2026 /PRNewswire/ — Webull Securities (Australia) Pty Ltd (“Webull Australia”), a subsidiary of Webull Corporation (NASDAQ: BULL), the owner of the Webull trading platform, today announced the removal of trading commission fees on US, Hong Kong, and China A-Share trades.

The change positions Webull as one of Australia’s lowest-brokerage-cost platforms for international share trading.

“We’ve set a new benchmark for trading fees in Australia,” said Rob Talevski, CEO of Webull Australia. “This is a fundamental change to how we price trades on the platform, made possible by the scale and global infrastructure of our Nasdaq-listed parent company.”

Commission-free trading has become prevalent in markets where tech-first brokers dominate market share. In Australia, that shift has been slower, as cash constraints among neo-brokers and legacy earnings models, tied to traditional brokers, have led to platform dependencies on higher fees.

Webull’s business model relies on scale and geographical expansion rather than high fees, and this is why it has been able to extend $0 pricing across the US, Hong Kong, and China A-Share markets simultaneously – all accessible from a single platform.

“The client journey used to be about picking a market they want to trade, then finding the platform that supports it. Now investors don’t have to make that trade-off,” Talevski added. “ASX and US ETFs, US equities, Hong Kong-listed stocks, China A-Shares – they’re all on the Webull platform, and they’re all now zero commission. We’re bringing the US trading culture of ‘zero commission trading’ to Australia. And we’re the first ones to do it so extensively.”

Webull’s international brokerage schedule changes are as follows:

• US Share Trading: previously 0.025% × trade value (minimum $1.00), all trading hours — now $0.
• Hong Kong Share Trading: previously $0.0003 × trade value (minimum $15) — now $0.
• China A-Shares: previously $0.0003 × trade value (minimum $15) — now $0. 

US and Australian ETFs, which Webull had already reduced to zero brokerage, will remain priced as such.

Webull’s platform provides access to CHESS-sponsored Australian equities and ETFs, US ETFs and equities, Hong Kong equities, China A-Shares, advanced US options, and cryptocurrencies. US markets are accessible 24 hours a day, five days a week.

Webull Australia is the WeMoney 2026 Award Winner for Best Low-Cost Broker.

Webull Australia is available via the Webull app. Users can open an account at www.webull.com.au.

###

About Webull Australia

Webull Securities (Australia) Pty. Ltd. is a leading financial services provider, holding an Australian Financial Services Licence (AFSL 536980) and regulated by the Australian Securities and Investments Commission (ASIC). As a trading participant of both the Australian Securities Exchange (ASX) and Cboe Australia (Cboe), and a principal member of the Stockbrokers and Investment Advisers Association, Webull strives to ensure the highest standards of service and security. Learn more at webull.com.au.

About Webull

Webull Corporation (NASDAQ: BULL) owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 14 markets across North America, Asia Pacific, Europe, and Latin America. Webull serves more than 26 million registered users globally, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies to work by trading global stocks, ETFs, options, futures, fractional shares, and digital assets through Webull’s trading platform, which seamlessly integrates market data and information, its user community, and investor education resources. Learn more at webullcorp.com.

Media Enquiries

Cognito for Webull: webull@cognitomedia.com.

PUNE, India, April 2, 2026 /PRNewswire/ — EKA Mobility, a leading electric vehicles and technology company, today announced a strong 5X year-on-year volume growth in FY 2025–26, with 1,143 units sold and 1,344 electric commercial vehicles produced. This milestone comes on the back of the company’s comprehensive electric vehicle portfolio across segments. During the year, EKA entered the M&HCV truck segment, in addition to its existing bus and SCV portfolio. The company is a Champion OEM under the Auto PLI Scheme and has achieved certification across multiple platforms.

EKA Mobility’s Range of Electric Commercial Vehicles (eBuses, eTrucks & eSCVs)

“FY 2025–26 is a defining year for EKA Mobility. We are not only scaling volumes but also expanding our manufacturing footprint by adding a new plant recently and increasing our planned annual capacity to 10,000 buses, 6,000 trucks and 24,000 SCVs. With the widest range of fully homologated, born-electric platforms from last-mile to long-haul, we are uniquely positioned as a full-stack EV company. Our growth across electric buses, small commercial vehicles, and now trucks validates both market demand and our execution capability.

India’s transition to clean commercial mobility is accelerating, and EKA is at the forefront driving this shift at scale, with technology, innovation, and global ambition.”

— Dr. Sudhir Mehta, Founder & Chairman, EKA Mobility

Strong Business Momentum Across Segments

• Electric Bus Leadership:
  Secured wins under PM e-Bus Sewa and PM E-DRIVE; deployed vehicles across 15+ states including Maharashtra, Gujarat, Uttar Pradesh, Karnataka, and Delhi
• SCV Breakout Year:
  Strong uptake of 3S & 6S passenger vehicles and 3W cargo platforms, accelerating last-mile mobility adoption
• Electric Trucks:
  New Growth Engine: Entry into heavy-duty trucks contributing to growth and expanding presence in logistics electrification
• Hydrogen Fuel Cell:
  Deployed a 9-metre hydrogen fuel cell bus at Cochin International Airport with KPIT Technologies and BPCL; plans to deploy 15 more buses

Key Highlights:

Global Expansion:

• Commenced electric bus deployments in Africa
• Partnership with Kerchanshe Group for CKD assembly and distribution
• Agreement with NBFI Capital for manufacturing in Australia

Manufacturing Scale-Up:

• Two Pune facilities operational; Pithampur plant to be operational shortly
• Planned annual capacity: 10,000 buses, 6,000 trucks and 24,000 SCVs

Retail Network:

• Expanded dealership network; plans to add 120 dealerships in FY27

Order Book Visibility:

• 6,000+ confirmed e-buses to be delivered over the next two years

About EKA Mobility

EKA Mobility is a Pune-based electric vehicle and technology company focused on transforming India’s commercial mobility landscape. With a portfolio spanning electric buses, electric trucks, and small commercial vehicles, EKA combines electric vehicle manufacturing with proprietary AI-powered fleet technology to deliver end-to-end mobility solutions.

EKA Mobility is backed by Mitsui & Co., Ltd. (Japan), VDL Groep (Netherlands), Pinnacle Industries Limited, Enam Holdings and the NIIF India-Japan Fund as equity and strategic partners and has expanded its footprint to markets in East Africa, South Africa, and Australia.

To know more about the company, kindly visit: https://ekamobility.com 

ALPHARETTA, Ga., April 2, 2026 /PRNewswire/ — Arclin, a global materials science company, today announced that it has completed the acquisition of DuPont’s Aramids business, including the renowned Kevlar® and Nomex® brands, for approximately $1.8 billion. The transaction marks a transformational milestone for Arclin, significantly expanding its scale, capabilities, and presence across life-critical industries. Arclin is a portfolio company of an affiliate of TJC, L.P.

Acquisition Fast Facts

“Kevlar® and Nomex® are the gold standard in their respective industries, and we are very excited to incorporate the Aramids platform into Arclin’s broader material science portfolio. This acquisition strategically strengthens Arclin’s operational and geographic footprint,” said Mark Glaspey, Arclin’s President. “With established manufacturing operations in Europe and Asia and ~1,800 new team members around the world, we are focused on operational continuity from day one while investing in manufacturing capabilities and innovation to support long-term growth.”

With the addition of the Aramids brands, Arclin’s portfolio now spans aerospace, electrical infrastructure, electric vehicles, and personal protection and defense. The acquisition further strengthens Arclin’s leadership across construction, infrastructure, transportation, and weather and fire protection as demand for advanced protective materials continues to grow. Arclin’s proprietary materials and technologies are mission-critical, supporting products that protect people, communities, and essential infrastructure worldwide.

“We’re excited to join the Arclin family and continue advancing the renowned performance that customers have relied on from Kevlar® and Nomex® for decades,” said Matt Reinhardt, Business Unit President for Aramids. “Our team’s deep expertise in aramid fiber technology, combined with Arclin’s commitment to investing in innovation and growth, positions us to better serve our customers and accelerate the development of next-generation protective solutions across industries.”

“Looking ahead, our mission is to build on the superior strength of the Aramids brands,” said Bradley Bolduc, Arclin’s Chief Executive Officer. “We’re focused on accelerating what these materials can do, putting meaningful investment behind technological innovation and deploying Kevlar® and Nomex® strategically across the world’s most performance-critical applications.”

Piper Sandler & Company served as financial advisor and Kirkland & Ellis LLP served as legal counsel to Arclin and TJC. Centerview Partners and Goldman Sachs & Co. LLC served as DuPont’s financial advisors and Skadden, Arps, Slate, Meagher & Flom LLP served as legal counsel.

About Arclin
Arclin is a leading materials science company and manufacturer of polymer technologies, engineered products, and specialized materials for the construction, agriculture, transportation infrastructure, weather & fire protection, pharmaceutical, nutrition, electronics, design, and other industries. Headquartered in Alpharetta, Georgia, Arclin has offices and manufacturing facilities across North & South America, Europe, and Asia and serves customers worldwide. For more information, visit www.arclin.com.

About TJC
TJC, L.P., formerly known as The Jordan Company, has worked for more than 40 years with CEOs, founders and entrepreneurs across a range of industries including Consumer, Diversified Industrials, Healthcare, Industrial Technology, Logistics & Business Services and Digital & Power Infrastructure. With $30.9 billion of assets under management as of September 30, 2025, TJC is managed by a senior leadership team that has invested together for over 24 years on over 90 investments. TJC has offices in New York, Chicago, Miami and Stamford. For more information, please visit www.tjclp.com.

About DuPont
DuPont (NYSE: DD) is a global innovation leader, providing advanced solutions that help transform industries and improve everyday life across our key markets of healthcare, water, construction, and industrial. More information about the company, its businesses and solutions can be found at www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

Arclin Media Contact
Jana Wright
Chief Marketing & Communications Officer
inquiries@arclin.com 

Kevlar® and Nomex® are registered trademarks of Arclin. DuPont™ is a trademark of affiliates of DuPont de Nemours, Inc.

Over 100 Zeus liner and heat shrink components will now be available to engineers through Chamfr’s online marketplace to accelerate medical device development.

ORANGEBURG, S.C., April 2, 2026 /PRNewswire/ — Zeus, a global leader in advanced polymer solutions and catheter manufacturing, announced a partnership with Chamfr to make more than 100 liner and heat shrink products readily available through Chamfr’s online marketplace. The collaboration gives device engineers faster, on-demand access to critical components used in catheter development and prototyping.

“We understand that speed-to-market can make all the difference in the success of an end device,” said Jim O’Connell, Chief Commercial Officer at Zeus. “By making Zeus components available through Chamfr, we’re giving engineers easier access to the materials they need to prototype, test, and advance their designs.”

Chamfr is the leading digital marketplace for medical device components, equipment, tools, and service providers, connecting manufacturers with engineers searching for high-performance materials to solve complex design challenges and speed up product development. By bringing Zeus products to the platform, engineers can more quickly discover, evaluate, and source the materials needed to develop next-generation medical technologies.

“Chamfr has built a powerful platform that connects engineers with the components they need to innovate faster – all in one place,” said Mike Evers, Director of Commercial Marketing at Zeus. “By partnering with Chamfr, we’re expanding access to the high-performance materials engineers rely on during early-stage development.”

Products available through the marketplace include FEP heat shrink, FluoroPEELZ™ peelable heat shrink, PTFE Sub-Lite-Wall™ liners, and PTFE StreamLiner™ catheter liners, with additional Zeus products expected to be added over time.

QUICK FACTS

• Zeus is partnering with Chamfr to add 100+ liner and heat shrink products to Chamfr’s online marketplace.
• The new partnership is designed to help medical device engineers expedite the prototyping and development of next-generation medical technologies.
• Zeus products added to the platform include a range of PTFE liners, FEP heat shrink, and FluoroPEELZ™ peelable heat shrink products.

For more information, visit: www.zeusinc.com/Chamfr

ABOUT ZEUS

Zeus, headquartered in Orangeburg, South Carolina, is the world’s leading polymer extrusion and catheter design manufacturer. More than 60 years of experience in medical, aerospace, energy, automotive, fiber optics, and more allows Zeus to achieve its mission to provide solutions, enable innovation, and enhance lives. The company employs over 2,200 people worldwide with facilities in Aiken, Columbia, Gaston, Orangeburg, St. Matthews, South Carolina; Branchburg, New Jersey; Chattanooga, Tennessee; San Jose, California; Arden Hills, Minnesota; Guangzhou, China; and Letterkenny, Ireland.

For more information, visit www.zeusinc.com

Pressing issues in oncology, including rising cancer incidences in younger people, plus global opportunities for improving outcomes, were presented alongside cutting-edge research and clinical guidelines updates, during yearly event hosted by the National Comprehensive Cancer Network.

ORLANDO, Fla., April 2, 2026 /PRNewswire/ — The National Comprehensive Cancer Network^® (NCCN^®)—a non-profit alliance of leading cancer centers—brought together more than a thousand oncology professionals at the NCCN 2026 Annual Conference in Orlando, Florida, with hundreds more joining virtually. This year’s event featured educational sessions on the latest breakthroughs in cancer prevention and treatment, clinical guidelines updates, guidance for improving cancer center operations, plus panel discussions on critical issues in care delivery.

The NCCN 2026 Annual Conference opened with a plenary session exploring the causes of an alarming rise in cancer incidence in people under 50, and how providers should adjust to this new reality. Learn more at NCCN.org/conference.

“We gain so much from gathering together to share ideas and best practices, make new connections, and forge new collaborations,” said Crystal S. Denlinger, MD, CEO, NCCN. “Conference attendees tell us they feel a renewed energy and hope for the future after discussing how cancer care has advanced over the past year. This helps us all serve our patients better and ensure they experience the best care and outcomes possible.”

The New Face of Cancer: Supporting Younger Adults Across the Care Continuum

The conference opened with a plenary session exploring the causes of an alarming rise in cancer incidence in people under 50, and how providers should adjust to this new reality. The panel members agreed that there are likely several contributing factors, including diet and lifestyle, microbiome, and environmental hazards.

Speakers noted that scheduling and financial toxicity are particularly troublesome for younger people who are at a different stage in their life and career when they embark on their cancer journey. Some may have complicated commitments due to young children while others may not be thinking about building a family yet or be aware of how treatment may impact fertility. Their experiences going through therapy can be isolating from both their peers—who are living very different lives—and their fellow patients, who are typically older.

The hope is that these patients go on to live for many years, making it particularly important to take long-term side effects from treatment into account. At the same time, adolescents and young adults are often diagnosed at a later stage due to being below the age threshold for screening, rarity making symptoms less likely to be identified, plus an increased likelihood of a genetic component. According to the panel, more education is needed within the healthcare community and beyond, to better prepare survivors and health care systems to achieve optimal results.

“All patients, but particularly early-onset adults, should have a full team providing multidisciplinary, holistic care,” said panel moderator Christopher Lieu, MD, University of Colorado Anschutz Cancer Center, Vice-Chair of the NCCN Board of Directors. “Adolescents and young adults with cancer have unique challenges and rely on supportive services to ensure good quality of life through treatment and for years to come.”

The speakers noted that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Adolescents and Young Adults (AYA) are a helpful resource on this topic.

Delivering Cancer Care Worldwide: Current Realities and Future Strategies

A second plenary session tackled cancer care around the world, with a focus on the growing burden and new opportunities to address it. The panel pointed out that cancer rates are rising dramatically and disproportionately, with the vast majority of deaths occurring in low- and middle-income countries (LMICs). However, only 5% of the world’s cancer funding is spent on these regions.

Speakers highlighted that there are numerous opportunities to make a significant difference with a big return on investment. Those include standardizing treatments worldwide while upscaling prevention—such as HPV-vaccination uptake and access to screening. But there are new challenges from funding cuts that undermine progress, plus siloed efforts that seek to reinvent the wheel. Staffing limitations and regional disparities in resources contribute to the burden.

“Well-conceived programs can make an incredible difference in these settings,” said panelist Anu K. Agrawal, MD, Vice President, Global Cancer Support, American Cancer Society (ACS). “A lot of people are very interested in helping; we just need them to work together. We must move swiftly to action and support cancer-related policies with practical resources.”

Speakers celebrated the collaboration between the African Cancer Coalition, ACS, and NCCN for creating and maintaining the International Adaptations of the NCCN Guidelines^® for Sub-Saharan Africa as one example of a program that is finding success. The panel also showcased the NCCN Guidelines Middle East and North Africa (MENA) Editions, a collaborative effort with the Ministry of National Guard—Health Affairs (Saudi Arabia). Learn more about these, and other initiatives, at NCCN.org/global.

Operational Excellence in Cancer Care

New this year for in-person attendees, NCCN offered an educational track on best practices for oncology program operations. It included sessions on the role of guidelines in addressing systemic and practical challenges to care, optimizing academic/community collaborations, artificial intelligence (AI) innovation and governance, and policy insights.

“The NCCN Guidelines were downloaded more than 18 million times last year. That is a sign that people want to do the right thing and provide the best care that they can,” said Lawrence N. Shulman, MD, MACP, FASCO, Abramson Cancer Center at the University of Pennsylvania, Member of the NCCN Best Practices Committee and Policy Advisory Group. “New advances have benefited our patients, who are living longer, which is great news. But they stay in our practices longer, and together with the growing number of new cancer patients in the U.S., our oncology work force is ever more strained. We need to make care more efficient with improved electronic health records (EHRs), other technologies, and reducing administrative burdens.”

New Research and More

The conference featured more than 300 original research abstracts, covering topics such as:

• Best Practices
• Bioinformatics/IT
• Case Studies
• Clinical Oncology
• Correlative/Genomic
• Epidemiology/Risks/Prevention
• Outcomes
• Pre-Clinical Oncology
• Quality Improvement
• Trials in Progress

In-person attendees had an opportunity to embark on expert-guided tours through both days of posters. Top abstracts on topics like “Integrating Print-to-Web Outreach into Mammography Workflows to Promote Lung Cancer Screening: A Feasibility Study,” “A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients with Metastatic Neuroendocrine Tumors (NETs),” and “Increasing Equitable Adherence to Annual Lung Cancer Screening and Diagnostic Surveillance: A Pragmatic Factorial Trial” were presented as talks during a live session. Past NCCN Foundation^® Young Investigator Award winners presented talks on topics including: “Evolving Toward Precision Oncology in Osteosarcoma” and “Characterizing the Peripheral T-cell Repertoire in Patients with Unresectable Melanoma Treated with IO102-IO103 and Nivolumab-relatlimab.”

The posters included an abstract from Taneal D. Carter, DHSc, MPA, MS, Senior Manager of the NCCN Cancer Care Equity Program, et. al., on a pilot project utilizing the Health Equity Report Card to assess and promote equitable practices in community care settings, through funding from the Alliance for Equity in Cancer Care.

Conference participants learned about clinical guideline updates for gastrointestinal, genitourinary, gynecologic, hematologic, and skin cancers, as well as case study discussions for breast and non-small cell lung cancers. Sessions also featured information on managing immune checkpoint inhibitor toxicities, clinical applications and emerging trends in AI technology, and other topics.

Next year, the NCCN Annual Conference moves to San Diego, California for the first time. Save the dates: Friday, March 19 – Sunday, March 21, 2027. Visit NCCN.org/conference to learn more.

About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network^® (NCCN^®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients^® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation^®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.

Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org

The NCCN 2026 Annual Conference featured more than 300 original research abstracts, Learn more at NCCN.org/conference.